Cornejo JP

Language: Spanish
References: 31
Page: 248-252
PDF size: 333.74 Kb.

ABSTRACT

Bacterial resistance has increased in recent years; it is associated with longer duration of hospitalization, increased in hospital costs and mortality. Escherichia coli is a bacterium, which is frequently isolated in hospital environment. When it has third generation cephalosporins resistance is related with the production of enzymes called extended-spectrum beta-lactamases (ESBL). Patients with hemato-oncological malignancies, particularly with fever and severe neutropenia (<500 cell/mm3) have a major risk for bacteremia. If they do not receive an appropriate antimicrobial treatment within the first 48 hours of symptoms, mortality is elevated. One of the main mechanisms for bacteremia in this group of patients is intestinal bacterial translocation. This is a review of E. coli-ESBL bacteremia in hemato-oncological patients and the importance of this disease.

REFERENCES

1. Peña C, Gudiol C, Calatayud L, Tubau F, et al. Infections due to Escherichia coli producing extended-spectrum betalactamase among hospitalized patients: factors influencing mortality. J Hosp Infect 2008;68:116-122.

2. Ramphal R, Ambrose PG. Extended-spectrum β-lactamases and clinical outcomes: current data. Clin Infect Dis 2006;42:164-172.

3. Rodríguez Baño J, Navarro MD, Romero L, Muniain MA, et al. Risk-factors for emerging bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Clin Microbiol Infect 2008;14:180-183.

4. Wu UI, Wang JL, Chen WC, Chang SC, et al. Risk factors and outcomes of Escherichia coli bacteremia caused by strains that produce CTX-M or non-CTX-M extended-spectrum-betalactamases. Eur J Clin Microbiol Infect Dis 2011;30:33-39.

5. Hu B, Ye H, Xu Y, Ni Y, et al. Clinical and economic outcomes associated with community-acquired intra-abdominal infections caused by extended spectrum beta-lactamase (ESBL) producing bacteria in China. Curr Med Res Opin 2010;26:1443-1449.

6. Hyle EP, Lipworth AD, Zaoutis TE, Nachamkin I, et al. Impact of inadequate initial antimicrobial therapy on mortality in infections due to extended-spectrum beta-lactamaseproducing Enterobacteriaceae. Arch Inter Med 2005; 27:1375-1380.

7. Peña C, Gudiol C, Tubau F, Sabalis M, Pujol M, et al. Riskfactors for acquisition of extended-spectrum beta-lactamaseproducing Escherichia coli among hospitalized patients. Clin Microbiol Infect 2006;12:279-284.

8. Lautenbach E, Patel JB, Bilker WB, Edelstein PH, et al. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis 2001;32:1162-1171.

9. Gudiol C, Calatayud L, García-Vidal C, Cisnal M, et al. Bacteraemia due to extended-spectrum beta-lactamaseproducing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome. J Antimicrob Chemother 2010;65:333-341.

10. Garza-González GE, Mendoza Ibarra SI, Llaca-Díaz JM, González GM. Molecular characterization and antimicrobial susceptibility of extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates at a tertiary-care centre in Monterrey, Mexico. J Med Microbiol 2011;60:84-90.

11. Trecarichi EM, Tumbarello M, Spanu T, Caira M, et al. Incidence and clinical impact of extended-spectrum-beta-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies. J Infect 2009;58:299-307.

12. Gales AC, Castanheira M, Jones RN, Sader HS. Antimicrobial resistance among Gram-negative bacilli isolated from Latin America: results from SENTRY Antimicrobial Surveillance Program (Latin America, 2008-2010). Diagn Microbiol Infect Dis 2012;73:354-60.

13. Mezel M, Petersen I. Mortality following bacteraemic infection caused by extended spectrum beta-lactamase (ESBL) producing E. coli compared to non-ESBL producing E. coli. J Infect 2007;55:254-259.

14. Cornejo Juárez P, Pérez Jiménez C, Silva Sánchez J, Velázquez Acosta C, et al. Molecular analysis and risk factors for Escherichia coli producing extended-spectrum β-lactamase bloodstream infection in hematological malignancies. PLoS One 2012;7: e35780.

15. Chen CY, Tsay W, Tang JL, Tien HF, et al. Epidemiology of bloodstream infections in patients with haematological malignancies with and without neutropenia. Epidemiol Infect 2009;27:1-8.

16. Wang FD, Lin ML, Liu CY. Bacteremia in patients with hematological malignancies. Chemotherapy 2005;51:147-153.

17. Van Leeuwen PAM, Boermeester MA, Houdijk APJ, Ferwerda ChC, et al. Clinical significance of translocation. Gut 1994;1:28-34.

18. O’Boyle CJ, MacFie J, Mitchell CJ, Johnstone D, et al. Microbiology of bacterial translocation in humans. Gut 1998;42:29-35.

19. Donelly JP, Blijlevens NMA, De Pauw BE. Infections in the immunocompromised host: General principles. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and Practice of Infectious Diseases. 7th ed. Philadelphia: Churchill Livingstone Elsevier, 2009;3781-3792.

20. Ramiro Puig E, Pérez Cano FJ, Castellote C, Franch A, et al. The bowel: A key component of the immune system. Madrid: Rev Esp Enferm Dig 2008;100:29-34.

21. Liss BJ, Vehreschild JJ, Cornely OA, Hallek M, et al. Intestinal colonisation and blood stream infections due to vancomycin-resistant enterococci (VRE) and extendedspectrum beta-lactamase-producing Enterobacteriaceae (ESBL) in patients with haematological and oncological malignancies. Infection 2012;40:613-619..

22. Kalambokis G, Tsianos EV. Endotoxaemia in the pathogenesis of cytopenias in liver cirrhosis. Could oral antibiotics raise blood counts? Med Hypotheses 2011;76:105-109.

23. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011;52:56-93.

24. Arnan M, Gudiol C, Calatayud L, Liñares L, et al. Risk factors for, and clinical relevance of, faecal extended-spectrum β-lactamase producing Escherichia coli (ESBL-EC) carriage in neutropenic patients with haematological malignancies. Eur J Clin Microbiol Dis 2011;30:355-360.

25. Yu WL, Chuang YCH, Rasmussen JW. Extended-spectrum beta-lactamases in Taiwan: epidemiology, detection, treatment and infection control. J Microbiol Immunol Infect 2006;39:264-277.

26. Andremont A, Sancho-Garnier H, Tancrede C. Epidemiology of intestinal colonization by members of the family Enterobacteriaceae highly resistant to erythromycin in a hematology-oncology unit. Antimicrob Agents Chemother 1986;29:1104-1107.

27. Blijlevens NMA, Donnelly JP, De Pauw BE. Mucosal barrier injury: biology, pathology, clinical counterparts and consequences of intensive treatment for haematological malignancy: an overview. Bone Marrow Transp 2000;25:1269-1278.

28. Calva JJ, Sifuentes-Osornio J, Cerón C. Antimicrobial resistance in fecal flora: longitudinal community-based surveillance of children from urban Mexico. Antimicrob Agents Chemother 1996;40:1699-1702.

29. Lautenbach E, Bilker WB, Tolomeo P, Maslow JN. Impact of diversity of colonizing strains on strategies for sampling Escherichia coli from fecal specimens. J Clin Microbiol 2008;46:3094-3096.

30. Valverde A, Coque TM, Sánchez-Moreno MP, Rollán A, et al. Dramatic increase in prevalence of fecal carriage of extended-spectrum beta-lactamase-producing Enterobacteriaceae during nonoutbreak situations in Spain. J Clin Microbiol 2004;42:4769-4775.

31. Lautenbach E, Tolomeo P, Mao X, Fishman NO, et al. Duration of outpatient fecal colonization due to Escherichia coli isolates with decreased susceptibility to fluoroquinolones: longitudinal study of patients recently discharged from hospital. Antimicrob Agents Chemother 2006;50:3939-3943.